Vaccine potency assay

DH David W. Hawman
KM Kimberly Meade-White
CC Chad Clancy
JA Jacob Archer
TH Troy Hinkley
SL Shanna S. Leventhal
DR Deepashri Rao
AS Allie Stamper
ML Matthew Lewis
RR Rebecca Rosenke
KK Kyle Krieger
SR Samantha Randall
AK Amit P. Khandhar
LH Linhue Hao
TH Tien-Ying Hsiang
AG Alexander L. Greninger
MJ Michael Gale, Jr
PB Peter Berglund
DF Deborah Heydenburg Fuller
KR Kyle Rosenke
HF Heinz Feldmann
JE Jesse H. Erasmus
request Request a Protocol
ask Ask a question
Favorite

LION/repRNA potency was assayed in vitro. Briefly, serial dilutions of LION/repRNA were incubated on a monolayer of BHK cells in a 96-well plate. Twenty-four hours later, cell lysates were added to an ELISA plate coated with anti-SARS-CoV2 Spike (S1 domain) monoclonal antibody (Genetex GTX632604). Following a primary incubation and washes, a polyclonal anti-SARS-CoV2 Spike (full-length S) primary antibody was added (Abcam Ab272504). Following a secondary incubation and washes, a secondary horse radish peroxidase (HRP)-conjugated antibody was used to detect S-specific binding (Genetex GTX213110-01). Following a final incubation, HRP activity was assayed by TMB/HCL detection and absorbance measured by plate reader (ELX808, Bio-Tek Instruments Inc) at 450nm.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A